Islamabad: Lucky Core Industries Limited (LCI) reported a 4.5% year-over-year rise in standalone earnings for fiscal year 2025, reaching PkR11.6 billion (EPS: PkR25.20), boosted by the acquisition of Pfizer's portfolio. This increase comes despite challenges in its Soda Ash division.

The company's Soda Ash revenue experienced a 16% decline to PkR39.8 billion due to an 18% drop in volumes, primarily attributed to reduced exports amid international pricing pressures. Polyester revenue saw a marginal 1% dip due to increased import competition. Meanwhile, Pharmaceutical revenue soared by 72% to PkR21 billion, largely due to the Pfizer portfolio's PkR7.2 billion contribution.

LCI's Chemical and Agri Science revenue fell by 2% and Animal Health revenue decreased by 10% due to market conditions. The firm's power needs for Soda Ash production are currently met primarily through coal. A new, more efficient boiler using a biomass mix is expected next month.

A new 70k tons per annum Dense Ash capacity came online this year, and an additional 200k tons per annum capacity is planned, pending local demand recovery. A new veterinary medicine facility is set to open early next year. Management forecasts robust pharmaceutical segment growth and solid polyester performance, but expects Soda Ash challenges to continue. LCI maintains a strong balance sheet with low debt.